spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  MULTI-LINK VISION 

 HSMN NewsFeed - 10 Jul 2013
Abbott Announces Approval of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent System in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 8 Jan 2013
Abbott Initiates Clinical Trial of Absorb(TM) in the United States
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2012
STENTYS Receives FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing(R) Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 6 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2009
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Jul 2008
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 2 Jun 2008
Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 14 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Apr 2008
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Jul 2007
Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Jun 2007
Abbott Submits XIENCE(TM) V Everolimus Eluting Coronary Stent System Application for U.S. FDA Approval
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
Abbott Announces Continued Positive Results with XIENCE(TM) V Everolimus Eluting Coronary Stent in SPIRIT Clinical Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT III U.S. Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Feb 2007
Abbott to Initiate First Study to Evaluate XIENCE(TM) V Everolimus Eluting Coronary Stent System in Treatment of Women With Cardiovascular Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2007
Private-Label Version of Abbott's XIENCE(TM)V Drug-Eluting Coronary Stent System Launches in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Jan 2007
French Court Rules in Favor of evYsio Medical Devices in Patent Litigation Against Abbott Laboratories
Devices Interventional Cardiology Litigation
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
MULTI-LINK VISION
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!